Transaction

jmetaB0270c15aace0080e8e8e0982982bfa99df485787202f7b6a8badd14adc2fd4f195@ff480c3f6b806a40db8cbd3d7a71d58b33e9a73d741436ecba5901d3cf3f147crss.itemmetarss.netM„<item> <title>Weight loss from Wegovy sustained for up to four years, trial shows</title> <link>https://arstechnica.com/?p=2024518</link> <comments>https://arstechnica.com/science/2024/05/long-term-wegovy-study-finds-weight-loss-plateaus-a-little-after-a-year/#comments</comments> <dc:creator><![CDATA[Beth Mole]]></dc:creator> <pubDate>Tue, 14 May 2024 23:04:37 +0000</pubDate> <category><![CDATA[Health]]></category> <category><![CDATA[Science]]></category> <category><![CDATA[cardiovascular disease]]></category> <category><![CDATA[heart attack]]></category> <category><![CDATA[obesity]]></category> <category><![CDATA[overweight]]></category> <category><![CDATA[semaglutide]]></category> <category><![CDATA[stroke]]></category> <category><![CDATA[wegovy]]></category> <category><![CDATA[weight loss]]></category> <guid isPermaLink="false">https://arstechnica.com/?p=2024518</guid> <description><![CDATA[It's still unclear how long people will have to stay on the drugs to maintain the effects.]]></description> <content:encoded><![CDATA[<div id="rss-wrap"> <figure class="intro-image intro-left"> <img src="https://cdn.arstechnica.net/wp-content/uploads/2023/11/GettyImages-1692436787-800x533.jpeg" alt="Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. "> <p class="caption" style="font-size:0.8em"><a href="https://cdn.arstechnica.net/wp-content/uploads/2023/11/GettyImages-1692436787-scaled.jpeg" class="enlarge-link" data-height="1706" data-width="2560">Enlarge</a> <span class="sep">/</span> Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. (credit: <a rel="nofollow" class="caption-link" href="https://www.gettyimages.com/detail/news-photo/still-life-of-wegovy-an-injectable-prescription-weight-loss-news-photo/1692436787?adppopup=true">Getty | Michael Siluk</a>)</p> </figure> <div><a name="page-1"></a></div> <p>A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then hit a plateau or "set point." But that early weight loss was generally maintained for up to four years while people continued taking the weekly injections.</p> <p>The findings, <a href="https://www.nature.com/articles/s41591-024-02996-7">published Monday in Nature Medicine</a>, come from a fresh analysis of data from the SELECT trial, which was designed to look at the drug's effects on cardiovascular health. The trial—a multicenter, double-blind, randomized, placebo-controlled trail—specifically enrolled people with existing cardiovascular disease who also had overweight or obesity, but did not have diabetes. In all, the trial included 17,604 people from 41 countries. Seventy-two percent of them were male, 84 percent were white, and the average age was about 62 years old.</p> <p>Last year, researchers <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2307563">published the trial's primary results</a>, which showed that semaglutide reduced participants' risk of heart attack, stroke, and cardiovascular-related deaths <a href="https://arstechnica.com/health/2023/11/obesity-drug-wegovy-reduces-cardiovascular-risks-for-those-at-high-risk/">by 20 percent</a> over the span of a little over three years.</p></div><p><a href="https://arstechnica.com/?p=2024518#p3">Read 5 remaining paragraphs</a> | <a href="https://arstechnica.com/?p=2024518&comments=1">Comments</a></p>]]></content:encoded> <wfw:commentRss>https://arstechnica.com/science/2024/05/long-term-wegovy-study-finds-weight-loss-plateaus-a-little-after-a-year/feed/</wfw:commentRss> <slash:comments>41</slash:comments> </item>